期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

40例乳腺癌新辅助化疗探讨

下载PDF
导出
摘要 目的 观察和探讨CAF方案在乳腺癌新辅助化疗应用中的临床疗效。方法 对40例乳腺癌患者，确诊后立即行以CAF方案新辅助化疗，化疗2～4个周期，每周期间隔21天。结果 术前达到临床完全缓解（cCR）2例，有效32例，其中PR20例、MR12例，有效率85％。化疗过程中，未出现严重的化疗毒性。结论 CAF方案新辅助化疗可为手术提供更多的选择机会，值得临床推广和应用。
作者 张衍胜 王建东
机构地区 山东省枣庄矿业集团枣庄医院普外科 中国人民解放军总医院普外科
出处 《中国临床医生杂志》 2006年第6期40-41,共2页 Chinese Journal For Clinicians
关键词 乳腺癌 新辅助化疗 临床疗效
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1Sobin LH, Wittekind Ch. TNM classification of malignant tumors[ M ]. 5th ed. New York : A John Wiley & Sons, 1997. 123 - 130.
  • 2林奇,周士福.乳腺癌新辅助化疗研究进展[J].医学综述,2004,10(12):718-721. 被引量：3
  • 3Gregory RK, Powles TJ , Salter J , et al. Prognostic relevance of cerbB2-expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy [ J ]. Breast Cancer Res Treat, 2000,59 ( 2): 171 - 175.
  • 4郝春芳,江泽飞,宋三泰.乳腺癌新辅助化疗若干问题的讨论[J].国外医学（肿瘤学分册）,2003,30(2):116-118. 被引量：20

二级参考文献38

  • 1Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 [J]. Cancer, 2002,95(4):681-695.
  • 2van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902[J]. J Clin Oncol, 2001,19(22): 4224-4237.
  • 3Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility [ J ]. Ann Surg Oncol,2002,9(3) : 228-234.
  • 4Ezzat AA, Ibrahim EM, Ajarim DS, et al . High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin [J]. Breast Cancer Res Treat, 2000,62(3):237-244.
  • 5Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer:preliminary data of a prospective randomized trial [ J ]. Clin Cancer Res, 2002,8(5): 1073-1079.
  • 6Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[J]. J Clin Oncol, 2002,20(6): 1456-1466.
  • 7NSABP. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27 [ J ].Breast Cancer Res Treat,2001,69:210a.
  • 8Wenzel C, Locker GJ, Pluschnig U, et al. Phase Ⅰ/Ⅱ trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer [J]. Cancer Chemother Pharmacol, 2002,50(2): 155-159.
  • 9Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy [J]. Breast Cancer Res Treat, 2000, 59(2): 171-175.
  • 10Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage Ⅱ and Ⅲ breast cancer: efficacy and correlative with biological markers in a phase Ⅱ, multicenter study [J]. Clin Cancer Res, 2003,9(2): 686-692.

共引文献19

中国临床医生杂志
2006年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部